Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 11/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475420 | 0.89 | OPRM1 (0.44) | CCR5OPRM1OGFRL1OPRK1OPRD1 | |
| SCHEMBL6476536 | 0.83 | OPRM1 (0.44) | CCR5OPRM1OGFRL1OPRK1OPRD1 | |
| SCHEMBL6476524 | 0.83 | OPRM1 (0.44) | CCR5OPRM1OGFRL1OPRK1OPRD1 | |
| SCHEMBL6213764 | 0.77 | OPRL1 (0.51) | CCR5OPRM1OGFRL1OPRK1OPRD1 | |
| SCHEMBL7463493 | 0.75 | OPRM1 (0.50) | OPRM1OGFRL1OPRK1OPRD1OPRL1 | |
| SCHEMBL7096310 | 0.72 | OPRM1 (0.47) | OPRM1OGFRL1OPRK1OPRD1OPRL1 | |
| SCHEMBL6476230 | 0.71 | OPRM1 (0.52) | OPRM1OGFRL1OPRK1OPRD1OPRL1 | |
| SCHEMBL7094878 | 0.70 | OPRM1 (0.45) | OPRM1OGFRL1OPRK1OPRD1OPRL1 | |
| SCHEMBL7094122 | 0.70 | CYP2D6 (0.52) | CCR5OPRM1OGFRL1OPRK1OPRD1 | |
| SCHEMBL7092534 | 0.70 | OPRM1 (0.49) | CCR5OPRM1OGFRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861425-B2 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | CCR5 292/4885OPRM1 4/4885OGFRL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.